Anti-VEGF Therapeutics Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025

Description

The global anti-vascular endothelial growth factor (anti-VEGF) therapeutics market is projected to grow from an estimated $24.4 billion in 2024 to $30.5 billion by 2030, reflecting a compound annual growth rate (CAGR) of 3.8% during the forecast period.

This growth is primarily driven by the increasing prevalence of ophthalmic diseases such as age-related macular degeneration (AMD), diabetic retinopathy (DR), macular edema, and retinal vein occlusion. The aging global population further contributes to the rising incidence of these conditions, thereby escalating the demand for effective treatments like anti-VEGF therapeutics. Additionally, significant investments in research and development, along with governmental and private funding for anti-VEGF treatment research, are propelling market expansion.

Key Insights

The largest disease category within the market is age-related macular degeneration (AMD), driven by its growing prevalence, particularly among the elderly. The sustained demand for anti-VEGF treatments in this segment is expected to drive significant market growth.

North America holds the largest share of the market, supported by advanced healthcare infrastructure, heightened awareness of ophthalmic conditions, and substantial investment in research and development. Meanwhile, the Asia-Pacific region is anticipated to witness the fastest growth, driven by an aging population, a rising prevalence of ophthalmic diseases, and improving healthcare access.

Ongoing research and development activities have resulted in a robust pipeline of anti-VEGF therapeutics. Recent FDA approvals for new treatments are expected to expand market opportunities by providing more options for patients and healthcare providers.

Significant funding from governmental bodies and private organizations is supporting research initiatives in anti-VEGF treatments. Studies demonstrate that early treatment with anti-VEGF agents can effectively slow the progression of vision-threatening conditions, such as diabetic retinopathy.

The COVID-19 pandemic adversely affected the market, as regulatory restrictions on elective procedures limited access to treatments. Supply chain disruptions further hindered operations during the peak of the pandemic. However, the market has since shown resilience with a recovery in patient access and treatment adoption.

The market remains consolidated, with key players focusing on strategic collaborations, product innovations, and expanding their geographical presence to maintain competitiveness.

Product Code: 12356

Chapter 1. Research Scope

1.1. Research Objectives
1.2. Market Definition
1.3. Analysis Period
1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by product
- 1.4.2. Market size breakdown, by disease
- 1.4.3. Market size breakdown, by distribution channel
- 1.4.4. Market size breakdown, by region
- 1.4.5. Market size breakdown, by country
1.5. Market Data Reporting Unit
- 1.5.1. Value
1.6. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
2.2. Primary Research
2.3. Market Size Estimation
2.4. Data Triangulation
2.5. Currency Conversion Rates
2.6. Assumptions for the Study
2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

5.1. Market Dynamics
- 5.1.1. Trends
- 5.1.2. Drivers
- 5.1.3. Restraints/challenges
- 5.1.4. Impact analysis of drivers/restraints
5.2. Impact of COVID-19
5.3. Porter's Five Forces Analysis
- 5.3.1. Bargaining power of buyers
- 5.3.2. Bargaining power of suppliers
- 5.3.3. Threat of new entrants
- 5.3.4. Intensity of rivalry
- 5.3.5. Threat of substitutes

Chapter 6. Global Market

6.1. Overview
6.2. Market Revenue, by Product (2019-2030)
6.3. Market Revenue, by Disease (2019-2030)
6.4. Market Revenue, by Distribution Channel (2019-2030)
6.5. Market Revenue, by Region (2019-2030)

Chapter 7. North America Market

7.1. Overview
7.2. Market Revenue, by Product (2019-2030)
7.3. Market Revenue, by Disease (2019-2030)
7.4. Market Revenue, by Distribution Channel (2019-2030)
7.5. Market Revenue, by Country (2019-2030)

Chapter 8. Europe Market

8.1. Overview
8.2. Market Revenue, by Product (2019-2030)
8.3. Market Revenue, by Disease (2019-2030)
8.4. Market Revenue, by Distribution Channel (2019-2030)
8.5. Market Revenue, by Country (2019-2030)

Chapter 9. APAC Market

9.1. Overview
9.2. Market Revenue, by Product (2019-2030)
9.3. Market Revenue, by Disease (2019-2030)
9.4. Market Revenue, by Distribution Channel (2019-2030)
9.5. Market Revenue, by Country (2019-2030)

Chapter 10. LATAM Market

10.1. Overview
10.2. Market Revenue, by Product (2019-2030)
10.3. Market Revenue, by Disease (2019-2030)
10.4. Market Revenue, by Distribution Channel (2019-2030)
10.5. Market Revenue, by Country (2019-2030)

Chapter 11. MEA Market

11.1. Overview
11.2. Market Revenue, by Product (2019-2030)
11.3. Market Revenue, by Disease (2019-2030)
11.4. Market Revenue, by Distribution Channel (2019-2030)
11.5. Market Revenue, by Country (2019-2030)

Chapter 12. Competitive Landscape

12.1. List of Market Players and their Offerings
12.2. Competitive Benchmarking of Key Players
12.3. Product Benchmarking of Key Players
12.4. Recent Strategic Developments

Chapter 13. Company Profiles

13.1. Biogen Inc.
- 13.1.1. Business overview
- 13.1.2. Product and service offerings
- 13.1.3. Key financial summary
13.2. F. Hoffmann-La Roche Ltd.
- 13.2.1. Business overview
- 13.2.2. Product and service offerings
- 13.2.3. Key financial summary
13.3. Sandoz Group AG
- 13.3.1. Business overview
- 13.3.2. Product and service offerings
- 13.3.3. Key financial summary
13.4. Bausch Health Companies Inc.
- 13.4.1. Business overview
- 13.4.2. Product and service offerings
- 13.4.3. Key financial summary
13.5. Viatris Inc.
- 13.5.1. Business overview
- 13.5.2. Product and service offerings
- 13.5.3. Key financial summary
13.6. Pfizer Inc.
- 13.6.1. Business overview
- 13.6.2. Product and service offerings
- 13.6.3. Key financial summary
13.7. Amgen Inc.
- 13.7.1. Business overview
- 13.7.2. Product and service offerings
- 13.7.3. Key financial summary
13.8. Regeneron Pharmaceuticals Inc.
- 13.8.1. Business overview
- 13.8.2. Product and service offerings
- 13.8.3. Key financial summary
13.9. Bayer AG
- 13.9.1. Business overview
- 13.9.2. Product and service offerings
- 13.9.3. Key financial summary
13.10. Novartis AG
- 13.10.1. Business overview
- 13.10.2. Product and service offerings
- 13.10.3. Key financial summary
13.11. AbbVie Inc.
- 13.11.1. Business overview
- 13.11.2. Product and service offerings
- 13.11.3. Key financial summary
13.12. Xbrane Biopharma AB
- 13.12.1. Business overview
- 13.12.2. Product and service offerings
- 13.12.3. Key financial summary

Chapter 14. Appendix

14.1. Abbreviations
14.2. Sources and References
14.3. Related Reports

Anti-VEGF Therapeutics Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025 - 2030)